There are reports of a significant deal involving Eli Lilly, with some outlets suggesting the company has acquired a psychedelics maker for $2.8 billion to develop a depression drug. However, other reports indicate a deal has been made for lower prices on obesity drugs, with some involving a Trump-backed initiative. The details and scope of the deal or deals are unclear, with conflicting information across different outlets.